You are here

Clinical Genomics Pathology Inc. receives licensure from Florida Agency for Healthcare Administration

BRIDGEWATER, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that its CLIA licensed and CAP accredited New Jersey laboratory is now licensed by the Florida Agency for Healthcare Administration to offer services for patients residing within the state of Florida.  Clinical Genomics is the sole provider of COLVERA™, a liquid biopsy ctDNA assay used to detect residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.

Dr. Lawrence LaPointe, President and CEO of Clinical Genomics, said, “This approval allows Florida doctors to offer COLVERA to their patients in one of the largest US oncology markets.”

“We are pleased to make available our world-class liquid biopsy testing to colorectal cancer surgeons and medical oncologists for the nearly 10,000 patients in Florida who are treated for colorectal cancer each year,” added Dr. John P. Alsobrook II, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology.

About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer.  Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA™, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.

Media Contact:
Patty Jenkins
+ 1.412.376. 2770

Tuesday, March 6, 2018 - 08:30